PureTech Founded Entity Seaport Therapeutics Prices $254.9 Million Upsized IPO

On May 1, 2026, PureTech Health plc announced that its founded entity, Seaport Therapeutics, Inc., priced its upsized initial public offering (IPO). Seaport is offering 14,160,000 shares of common stock at a price of $18.00 per share, which is at the top of its target range. The gross proceeds from the offering are expected to be approximately $254.9 million before underwriting discounts and commissions. Seaport has also granted underwriters a 30-day option to purchase up to an additional 2,124,000 shares. The shares are scheduled to begin trading on the Nasdaq Global Select Market on May 1, 2026, under the ticker symbol 'SPTX,' with the offering expected to close on May 4, 2026. Upon the closing of the IPO, PureTech Health will hold 16,685,013 shares of Seaport common stock. Seaport Therapeutics is a clinical-stage company focused on developing neuropsychiatric medicines using its proprietary Glyph platform to improve the delivery of clinically validated mechanisms.